 HAMPTON, N.J., April 12, 2021 GLOBE NEWSWIRE -- Celldex Therapeutics, Inc. Nasdaq:CLDX today announced the presentation of promising data from the Companys growing bispecific platform at the American Association of Cancer Research AACR Annual Meeting 2021 being held April 10th 15th. The Company described the discovery and characterization of ILT4 inhibitory monoclonal antibodies mAbs for engineering bispecific antibodies bsAbs that revert myeloid cell suppression by antagonizing ILT4 and activate T-cell responses through PD-L1 inhibition poster 1865. Based on the results reported today, Celldex is developing clinical bispecific candidates that co-target ILT4 and PD-L1. 